Skip to main content
SpringerLink
Log in

Current status of immunotherapy for cancer treatment

  • Editorial
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med, 306(9): 517–522, 1982

    Article  PubMed  CAS  Google Scholar 

  • Boyiadzis M, Foon KA. Approved monoclonal antibodies for cancer therapy. Expert Opin Biol Ther, 8(8): 1151–1158, 2008

    Article  PubMed  CAS  Google Scholar 

  • Fiegl M, Gastl G, Hopfinger G, et al. Alemtuzumab in chronic lymphocytic leukemia, other lymphoproliferative disease and autoimmune disorders. memo, 1(4): 2008 (this issue)

  • Nagorsen D, Rüttinger D. Immunotherapy of colorectal cancer. memo, 1(4): 2008 (this issue)

  • Hess G. Radioimmunotherapy – still experimental? Rational, proven indications and future trends. memo, 1(4): 2008 (this issue)

  • Ricart AD, Tolcher AW. Technology insight: cytotoxic drug immunoconjugates for cancer therapy. Nat Clin Pract Oncol, 4(4): 245–255, 2007

    Article  PubMed  CAS  Google Scholar 

  • Davies AJ. Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab. Oncogene, 26(25): 3614–3628, 2007

    Article  PubMed  CAS  Google Scholar 

  • Zhang MM, Gopal AK. Radioimmunotherapy-based conditioning regimens for stem cell transplantation. Semin Hematol, 45(2): 118–125, 2008

    Article  PubMed  CAS  Google Scholar 

  • Finn OJ. Cancer immunology. N Engl J Med, 358(25): 2704–2715, 2008

    Article  PubMed  CAS  Google Scholar 

  • Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol, 24(19): 3089–3094, 2006

    Article  PubMed  CAS  Google Scholar 

  • Greiner J, Schmitt M. Current status of peptide vaccines for cancer immunotherapy in malignant myeloid diseases. memo, 1(4): 2008 (this issue)

  • Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science, 305(5681): 200–205, 2004

    Article  PubMed  CAS  Google Scholar 

  • Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumour-infiltrating lymphocytes. Science, 233(4770): 1318–1321, 1986

    Article  PubMed  CAS  Google Scholar 

  • Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, et al. Treatment of metastatic melanoma with autologous CD4+ T-cells against NY-ESO-1. N Engl J Med, 358(25): 2698–2703, 2008

    Article  PubMed  CAS  Google Scholar 

  • Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol, 24: 99–146, 2006

    Article  PubMed  CAS  Google Scholar 

  • Ghiringhelli F, Puig PE, Roux S, Parcellier A, Schmitt E, Solary E, et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T-cell proliferation. J Exp Med, 202(7): 919–929, 2005

    Article  PubMed  CAS  Google Scholar 

  • Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol, 6(4): 295–307, 2006

    Article  PubMed  CAS  Google Scholar 

  • Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med, 13(1): 54–61, 2007

    Article  PubMed  CAS  Google Scholar 

  • Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T-cell-engaging antibody. Science, 321(5891): 974–977, 2008

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Tyrolean Cancer Research Center, Internal Medicine V (Haematology and Oncology) and Laboratory of Tumourimmunology, Medical University Innsbruck, Innsbruck, Austria

    D. Wolf

Authors
  1. D. Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Wolf.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wolf, D. Current status of immunotherapy for cancer treatment. memo 1, 190–192 (2008). https://doi.org/10.1007/s12254-008-0061-y

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-008-0061-y

Search

Navigation